India To Use Ranbaxy Bid For Parity In Japanese Trade Talks
This article was originally published in PharmAsia News
India's government plans to take advantage of Daiichi Sankyo's bid to buy Ranbaxy Laboratories in its current negotiations with Japan for a bilateral trade and investment agreement. Indian negotiators plan to use the case to press Japan to make its highly protected drug makers susceptible to similar buyout bids by Indian companies. The two countries are negotiating a comprehensive economic partnership agreement, with the next meeting set for next month in Tokyo. An Indian commerce official said Japan has regulations that make it harder for foreign companies to buy into Japanese firms. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.